Orphazyme AS (CHIX:ORPHAC) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Orphazyme AS's cash to debt ratio for the quarter that ended in Jun. 2022 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Orphazyme AS could pay off its debt using the cash in hand for the quarter that ended in Jun. 2022.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Orphazyme AS's Cash-to-Debt or its related term are showing as below:

CHIX:ORPHAc's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.39
* Ranked among companies with meaningful Cash-to-Debt only.

Orphazyme AS Cash-to-Debt Historical Data

The historical data trend for Orphazyme AS's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Orphazyme AS Cash-to-Debt Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.60

10.28

2.56

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Cash-to-Debt	Get a 7-Day Free Trial									7.54	10.28	5.70	2.56	No Debt

Competitive Comparison of Orphazyme AS's Cash-to-Debt

For the Biotechnology subindustry, Orphazyme AS's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orphazyme AS's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's Cash-to-Debt falls into.

Orphazyme AS Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Orphazyme AS's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	102.255	/	(33.561	+	6.407)
	=	2.56

Orphazyme AS's Cash to Debt Ratio for the quarter that ended in Jun. 2022 is calculated as:

Orphazyme AS had no debt ⁽¹⁾.

Orphazyme AS (CHIX:ORPHAc) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Orphazyme AS Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines

Orphazyme AS (CHIX:ORPHAC) Cash-to-Debt : No Debt (1) (As of Jun. 2022)